top of page

Chief Medical Officer (CMO)

Benjamin Zhang, MD

Chief Medical Officer (CMO) of

YD Biopharma, JY Biomedical

Dr. Benjamin Zhang is a pioneering leader in cancer immunotherapy and regenerative medicine, with significant expertise in immune cell research, stem cell therapy, and clinical trial management. As the Chief Medical Officer at YD Biopharma, Dr. Zhang drives the company’s cutting-edge efforts in gamma delta T cell expansion and exosome therapy for cancer treatment. He also serves as the CMO of JY Biomedical, where he oversees clinical operations and the development of advanced cancer therapies.

At YD Biopharma, we are committed to translating cutting-edge research into tangible benefits for patients. By fostering innovation and collaboration, we strive to shape the future of cancer care and regenerative medicine, bringing hope to those in need.

IMG_5592 2.jpg

Academic Excellence

M.D., School of Medicine, Taipei Medical University (2017–2023)

Comprehensive training in clinical medicine, research methodologies, and patient-centered care.

醫生檢查血壓

Professional Achievements

"METHOD FOR THE PRODUCTION OF GAMMA DELTA T CELLS FOR IMMUNOTHERAPY APPLICATIONS", U.S. Patent Application No.: 63/742,633

Publishing breakthrough research in high-impact journals like Int J Mol Sci, Cancers, and Biochim Biophys Acta.

Overseeing clinical trials and regulatory submissions to ensure the safety and efficacy of cancer therapies.

Image by Lewis Keegan

Entrepreneurial Ventures

YD Biopharma

Leading innovations in precision medicine and exosome therapies, with a focus on early cancer detection and Limbal Stem Cell Exosome Therapy.

JY Biomedical

Developing cancer vaccines, cell therapies, and regenerative medicine solutions, in collaboration with major partners such as Hexun Biosciences and 3D Global Biotech.

皮革公文包

Philanthropy and Leadership

Dr. Zhang is deeply committed to advancing global healthcare and improving patient outcomes. He is involved in multiple philanthropic initiatives focused on enhancing access to groundbreaking therapies, particularly in cancer treatment and regenerative medicine.

Image by Louis Hansel
bottom of page